X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (191) 191
Patent (158) 158
Publication (32) 32
Book Chapter (10) 10
Book / eBook (3) 3
Book Review (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (151) 151
hygiene (147) 147
medical or veterinary science (147) 147
preparations for medical, dental, or toilet purposes (147) 147
chemistry (139) 139
metallurgy (139) 139
organic chemistry (139) 139
heterocyclic compounds (115) 115
humans (82) 82
specific therapeutic activity of chemical compounds ormedicinal preparations (82) 82
acyclic or carbocyclic compounds (79) 79
animals (57) 57
index medicus (51) 51
mice (34) 34
mutation (31) 31
biochemistry (29) 29
cancer (27) 27
oncology (26) 26
beer (25) 25
cell line, tumor (25) 25
compositions thereof (25) 25
culture media (25) 25
enzymology (25) 25
microbiology (25) 25
microorganisms or enzymes (25) 25
mutation or genetic engineering (25) 25
propagating, preserving or maintaining microorganisms (25) 25
spirits (25) 25
vinegar (25) 25
wine (25) 25
peptides (24) 24
proto-oncogene proteins b-raf - genetics (24) 24
article (21) 21
cell biology (21) 21
multidisciplinary sciences (21) 21
proto-oncogene proteins b-raf - antagonists & inhibitors (21) 21
research (21) 21
melanoma (20) 20
biochemistry & molecular biology (19) 19
tumors (19) 19
activation (18) 18
sulfonamides - pharmacology (17) 17
braf (16) 16
genetic aspects (16) 16
indoles - pharmacology (16) 16
compositions or test papers therefor (15) 15
condition-responsive control in microbiological orenzymological processes (15) 15
kinases (15) 15
measuring or testing processes involving enzymes, nucleicacids or microorganisms (15) 15
mutations (15) 15
processes of preparing such compositions (15) 15
signal transduction (15) 15
agriculture (14) 14
female (14) 14
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (14) 14
animal husbandry (13) 13
fishing (13) 13
forestry (13) 13
hunting (13) 13
kinase (13) 13
male (13) 13
molecular sequence data (13) 13
protein kinase inhibitors - pharmacology (13) 13
trapping (13) 13
b-raf (12) 12
melanoma - drug therapy (12) 12
pathway (12) 12
phosphorylation (12) 12
proto-oncogene proteins b-raf - metabolism (12) 12
resistance (12) 12
expression (11) 11
gene (11) 11
gtpase-activating proteins (11) 11
guanosine triphosphate - metabolism (11) 11
map kinase signaling system - drug effects (11) 11
ras gtpase-activating proteins (11) 11
care and treatment (10) 10
care of birds, fishes, insects (10) 10
drug therapy (10) 10
new breeds of animals (10) 10
proteins (10) 10
ras (10) 10
rearing or breeding animals, not otherwise provided for (10) 10
vemurafenib (10) 10
amino acid sequence (9) 9
biological sciences (9) 9
cells (9) 9
colony-stimulating factor (9) 9
health aspects (9) 9
kinetics (9) 9
proliferation (9) 9
proteins - metabolism (9) 9
ras proteins - metabolism (9) 9
acquired-resistance (8) 8
antineoplastic agents - pharmacology (8) 8
base sequence (8) 8
cell line (8) 8
cells, cultured (8) 8
gene expression (8) 8
gene mutations (8) 8
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (333) 333
French (42) 42
Chinese (17) 17
German (17) 17
Spanish (9) 9
Russian (6) 6
Portuguese (5) 5
Korean (3) 3
Danish (2) 2
Greek (2) 2
Norwegian (2) 2
Slovenian (2) 2
Hungarian (1) 1
Polish (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 03/2010, Volume 464, Issue 7287, pp. 427 - 430
Tumours with mutant BRAF are dependent on the RAF–MEK–ERK signalling pathway for their growth. We found that ATP-competitive RAF inhibitors inhibit ERK... 
SELECTIVE INHIBITOR | ACTIVATION | MELANOMA | MECHANISM | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | HETERODIMERIZATION | KINASE INHIBITOR | B-RAF | CRAF | ONCOGENIC BRAF | Neoplasms - metabolism | ras Proteins - genetics | Phosphorylation | raf Kinases - antagonists & inhibitors | Humans | Protein Multimerization | Transcriptional Activation - drug effects | ras Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | raf Kinases - metabolism | Mitogen-Activated Protein Kinase Kinases - metabolism | Neoplasms - genetics | Adenosine Triphosphate - metabolism | Indoles - pharmacology | raf Kinases - genetics | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Cell Line | raf Kinases - chemistry | Catalytic Domain | Neoplasms - enzymology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | MAP Kinase Signaling System - drug effects | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Protein Binding | Mice | Protein Kinase Inhibitors - pharmacology | Protein Kinase Inhibitors - metabolism | Care and treatment | Enzyme inhibitors | Gene mutations | Cellular signal transduction | Genetic aspects | Research | Health aspects | Cancer | Proteins | Competition | Drugs | Mutation | Kinases | Tumors | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 02/2016, Volume 76, Issue 3 Supplement, pp. IA32 - IA32
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2015, Volume 21, Issue 4 Supplement, pp. IA15 - IA15
Journal Article
Molecular Cancer Research, ISSN 1541-7786, 12/2014, Volume 12, Issue 12 Supplement, pp. IA05 - IA05
Journal Article
Nature, ISSN 0028-0836, 09/2010, Volume 467, Issue 7315, pp. 596 - 599
B-RAF is the most frequently mutated protein kinase in human cancers(1). The finding that oncogenic mutations in BRAF are common in melanoma(2), followed by... 
ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | MUTATION | KERATOACANTHOMAS | SENSITIVITY | SENESCENCE | SORAFENIB | HUMAN CANCER | PROGRESSION | BRAF(V600E) | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Macaca fascicularis | Melanoma - enzymology | Substrate Specificity | Positron-Emission Tomography | Extracellular Signal-Regulated MAP Kinases - metabolism | Indoles - administration & dosage | Neoplasm Metastasis | Melanoma - genetics | Phosphorylation - drug effects | Mutant Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Sulfonamides - chemistry | Mutant Proteins - genetics | Models, Molecular | Rats | Mutant Proteins - metabolism | Melanoma - pathology | Mutation - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Xenograft Model Antitumor Assays | Animals | Indoles - adverse effects | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutant Proteins - chemistry | Alleles | Dogs | Sulfonamides - adverse effects | Indoles - therapeutic use | Indoles - chemistry | Sulfonamides - administration & dosage | Control | Gene mutations | Melanoma | Development and progression | Genetic aspects | Research | Health aspects | Protein kinases | Cancer | Proteins | Mutation | Kinases | Rodents | Index Medicus | targeted therapy | melanoma | BRAF | PLX4032 | biomarker | oncogene
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 3, pp. 207 - 215
Patients with melanoma who are treated with a BRAF inhibitor have a high incidence of keratoacanthomas. Most of the tumors have oncogenic mutations in HRAS... 
MEDICINE, GENERAL & INTERNAL | ACTIVATION | MELANOMA | CARCINOGENESIS | PLX4032 | PATHWAY | KINASE | RESISTANCE | PROLIFERATION | LINES | VEMURAFENIB | p53 Protein | MEK inhibitors | Extracellular signal-regulated kinase | MAP kinase | Ras protein | Kinases | Patients | Carcinogenesis | Proteins | Protein kinase | Transcription activation | Rodents | Cell lines | Skin | Mutation | Index Medicus | Abridged Index Medicus
Journal Article
Nature, ISSN 0028-0836, 10/2015, Volume 526, Issue 7574, pp. 583 - 586
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2010, Volume 107, Issue 33, pp. 14903 - 14908
Tumors with mutant BRAF and some with mutant RAS are dependent upon ERK signaling for proliferation, and their growth is suppressed by MAPK/ERK kinase (MEK)... 
Tumor cell line | Phosphorylation | Cell growth | Negative feedback | Genes | Cell lines | Melanoma | Genetic mutation | Tumors | Cancer | LUNG-CANCER | APOPTOSIS | KINASE KINASE-1/2 INHIBITOR | ACTIVATION | PATHWAY | MULTIDISCIPLINARY SCIENCES | IN-VIVO | B-RAF | MUTATIONS | MEK INHIBITORS | ADVANCED CANCERS | Diphenylamine - pharmacology | Oligonucleotide Array Sequence Analysis | Apoptosis - drug effects | Humans | Gene Expression Profiling | Extracellular Signal-Regulated MAP Kinases - metabolism | Diphenylamine - analogs & derivatives | Mitogen-Activated Protein Kinase Kinases - metabolism | Indoles - pharmacology | Benzamides - pharmacology | G1 Phase - genetics | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Proto-Oncogene Proteins B-raf - metabolism | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Blotting, Western | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Cell Line, Tumor | Cell Proliferation - drug effects | Mutation | Amino Acid Substitution | Cell proliferation | Development and progression | Cellular signal transduction | Genetic aspects | Pharmacology | Research | Drug therapy | Index Medicus | Biological Sciences
Journal Article